# Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

> **NCT05098210** · PHASE1 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Locally Advanced Cutaneous Melanoma
- Locally Advanced Mucosal Melanoma
- Metastatic Acral Melanoma
- Metastatic Conjunctival Melanoma
- Metastatic Cutaneous Melanoma
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Mucosal Melanoma
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Recurrent Cutaneous Melanoma
- Recurrent HER2-Negative Breast Carcinoma
- Recurrent Hormone Receptor-Positive Breast Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Mucosal Melanoma
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Unresectable Acral Melanoma
- Unresectable Cutaneous Melanoma
- Unresectable Lung Non-Small Cell Carcinoma
- Unresectable Mucosal Melanoma

## Interventions

- **BIOLOGICAL:** Neoantigen Peptide Vaccine
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Poly ICLC
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05098210
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098210, "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05098210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*